Navigation Links
Weikang Bio-Technology Group Co., Inc. Is Expected to Achieve the Net Profit of at Least $26 Million
Date:2/27/2012

HARBIN, China, Feb. 27, 2012 /PRNewswire-Asia-FirstCall/ --  Weikang Bio-Technology Group Co., Inc. (WKBT.PK)("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company is expected to report its fiscal 2011 net profit of between $26 million to $28 million with EPS between $0.78 and $0.84 and revenue between $100 million and $102 millions.

"We are excited and confident about our results for 2011 and growth prospects beyond. The economy in China as we feel in general is slowing down, however we believe that the market for our high-quality therapeutics and health enhancement will continue to expand as China is expected to become the second largest pharmaceutical market by 2020," commented Mr. Yin Wang, Chairman and CEO of Weikang. "Moreover, our pipeline products on which our research team is focused address a large number of health problems and have a broad consumer appeal."

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang Pharmaceutical Co., Ltd.  For more information, please visit http://www.weikangbio.com.

Contact:
Yue Kang (Venus)
+86 451-8835-5530
+86 15846588061 
Email: weikangbio@yahoo.com

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.


'/>"/>
SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Weikang Bio-Technology Reports Second Quarter 2010 Financial Results
2. Weikang Bio-Technology to Present at Rodman and Renshaws Annual Global Investment Conference on September 14th 2010
3. Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance
4. Weikang Bio-Technology Announces Fiscal 2010 Financial Results
5. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
6. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
7. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
8. KJT Group Positions for Substantial Growth
9. Bill Pollock, President and CEO of Pharmagistics Group, Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences
10. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
11. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Diego, CA (PRWEB) , ... April 29, 2016 , ... ... Foundation (NSCF) to support the development of a patient-specific stem cell therapy for the ... in the lab of Dr. Jeanne Loring at The Scripps Research Institute in San ...
(Date:4/28/2016)... ... April 28, 2016 , ... Connecticut Innovations ... growing companies, today announced the launch of VentureClash , a $5 million ... , “VentureClash looks to attract the best early-stage companies here in Connecticut, ...
(Date:4/27/2016)... ... ... Shimadzu Scientific Instruments (SSI) will be showcasing a broad ... Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, moisture, ... booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, peak ...
(Date:4/27/2016)... ... April 27, 2016 , ... The ... announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined ... of the founding commercial leaders responsible for the commercialization of multiple orphan drug ...
Breaking Biology Technology:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):